Legend Biotech Corporation reports news on cell therapy development and commercialization, centered on CARVYKTI® (ciltacabtagene autoleucel), a CAR-T therapy for relapsed or refractory multiple myeloma developed and marketed with Johnson & Johnson. Company updates commonly cover CARVYKTI sales trends, treatment-site expansion, manufacturing capacity, clinical and real-world data from the CARTITUDE program, and label or evidence developments tied to multiple myeloma care.
Legend Biotech news also follows its broader cell therapy pipeline, including allogeneic and in vivo CAR-T programs such as LUCAR-G39D in B-cell non-Hodgkin lymphoma. Recurring announcements include quarterly financial results, scientific-conference presentations, research and manufacturing priorities, advisory input, and corporate governance updates.
Legend Biotech Corporation (NASDAQ: LEGN) will participate in the Jefferies Virtual Cell Therapy Summit on October 6th. Ying Huang, interim CEO and CFO, will represent the company during the session at 11:20 a.m. ET. The event can be accessed via the Legend Biotech website for investors and interested parties. Legend Biotech focuses on developing innovative cell therapies for oncology and other diseases, and is collaborating with Janssen Biotech on its lead candidate, ciltacabtagene autoleucel, which is undergoing clinical trials for multiple myeloma.